Veerhealth Care Eyes Breakout Year With Fresh Export Wins And Bold Revenue Forecast

Veerhealth Care Ltd, a rising player in India’s Ayurvedic and personal care segment, has announced a new export order worth 2 million rupees alongside an ambitious revenue forecast of 300 to 350 million rupees for the financial year 2025–26. The twin developments signal a strong growth trajectory for the Mumbai-based company, which has been steadily expanding its global footprint and product portfolio. With fresh orders from institutional buyers and a revamped manufacturing base, Veerhealth is positioning itself for a transformative year.

 

Here are the most relevant updates from the company’s latest disclosures:

 

Fresh Export Order From US Institutional Buyer

 

- Veerhealth Care has received a 2 million rupee export order from an existing institutional client in the United States  

- The order includes oral care products under the company’s Ayuveer brand, known for its natural and Ayurvedic formulations  

- This shipment is part of a broader export pipeline, with the company expecting monthly repeat orders and annual volumes of up to 180 million rupees from the same buyer  

 

Revenue Guidance For FY 2025–26

 

- The company has projected total revenue of 300 to 350 million rupees for FY 2025–26, a sharp increase from 146.1 million rupees reported in FY 2023–24  

- This growth is expected to be driven by full-capacity operations at its Vapi plant, which is undergoing renovation to meet US FDA and WHO compliance standards  

- Veerhealth anticipates a profit after tax margin of around 10 percent, supported by higher export volumes and improved operational efficiency  

 

Manufacturing Expansion And Regulatory Milestones

 

- The Vapi facility is being upgraded to meet cGMP norms, with operations slated to begin in October 2025  

- The plant will support four to five full-container-load shipments per month, enabling the company to meet rising demand from overseas clients  

- Veerhealth is also exploring new export markets, including Russia, where it is in advanced talks with a major oral care distributor  

 

Product Diversification And New Business Verticals

 

- In addition to oral care, the company is expanding into medical devices and hospital care through a newly launched division  

- This vertical will focus on ventilators, infusion pumps, syringe pumps, and defibrillators, targeting government contracts and institutional buyers  

- Veerhealth’s plastic molding unit, VeerPlast, is also ramping up toothbrush production to support its oral care business  

 

Financial Performance And Market Sentiment

 

- In FY 2023–24, Veerhealth reported a profit before tax of 12.8 million rupees, reflecting strong margin discipline despite regulatory delays  

- The company has already executed and shipped orders worth 30 million rupees out of a total export pipeline of 45 million rupees  

- Shares of Veerhealth Care Ltd were trading flat at 23.98 rupees on the BSE, with investors awaiting further updates on plant commissioning and export volumes  

 

Leadership Commentary And Strategic Outlook

 

- Managing Director Bhavin Shah stated that the latest export order validates the company’s quality standards and global competitiveness  

- He emphasized that Veerhealth is committed to long-term partnerships and sustainable growth, with a focus on regulatory compliance and customer satisfaction  

- The company aims to build a recurring export revenue stream and expand its presence in high-margin international markets  

 

Conclusion

 

Veerhealth Care Ltd’s latest export order and bold revenue forecast reflect a company on the cusp of significant transformation. With regulatory upgrades, diversified product lines, and expanding global partnerships, Veerhealth is laying the foundation for sustained growth and profitability. As it moves into FY 2025–26, the company’s strategic focus on quality, compliance, and innovation will be key to unlocking new opportunities in both domestic and international markets.

 

Sources: Business Standard, The Hindu BusinessLine, FinanceSaathi.